Funding profile · Precision oncology software

Cambridge Cancer Genomics

About $4.5 million of seed capital, no Form D, no Series A, and a set of UK accounts that show exactly how far the money went. Acquired in June 2021, dissolved in January 2023.

$4.5MSeed capital raised, per Forbes and Business Weekly, Feb 2019
£3.36MShares issued by the UK company to its Delaware parent, Jul 2020
0Form D filings on SEC EDGAR, and zero charges at Companies House
£33,886Cash at bank at 31 Jul 2021, fourteen months before the strike off

Data as of September 23, 2026. Company-reported figures are labeled.

Rounds at a glance

When Round Amount Investors Source
To Aug 2017 Pre-seed, then a targeted seed $1.3M target Not named TechCrunch
2017 Y Combinator batch and demo day Not disclosed Y Combinator; Pi Campus invested after demo day Accelerator, investor
Dec 14, 2018 Round labelled Series A by one database Withheld Y Combinator, AME Cloud Ventures, Romulus Capital named Database
By Feb 2019 Seed, cumulative About $4.5M Backing described by the company as mostly San Francisco based Forbes, Business Weekly
Jul 3, 2020 Allotment in the UK subsidiary £3,357,375 Cambridge Cancer Genomics, Inc, at £1 per share including premium Companies House
Q1 2020 Series A, planned $20M to $50M suggested Never announced Never filed or reported
Jun 2021 Acquisition by Dante Labs Not disclosed Dante Labs Company release

What the filings show

Cambridge Cancer Genomics Ltd. · company 10583580 · register entry

Incorporated
25 January 2017, England and Wales, SIC 72110
Share capital
£150, being 15,000,000 ordinary shares of £0.00001, then £183.57 after July 2020
Charges
0 registered, so no secured lending
Directors
J W Cassidy throughout; Cambridge Applied Research to 1 Dec 2021; Clifford, Patel and Tsai resigned 19 Jul 2017
Ending
Strike off application 5 Oct 2022, dissolved 17 Jan 2023

Cambridge Cancer Genomics Ltd. · accounts · five filings, 2018 to 2022

Cash at bank
£981,051, £588,801, £291,458, £33,886, £142,699
Accumulated losses
£354,217, £1,585,028, £2,491,042, £3,507,815, then £3,198,326
Parent funding
Creditors due after one year of £1,372,755 and £2,321,683, then nil, with £3,357,375 as other equity
Employees
Average 3, then 12, then 18 to 31 Jan 2020, then nil
Options
615,500 EMI options to 15 employees at $0.00001
Audit
Every filing unaudited, small company and audit exemption regimes

Cambridge Cancer Genomics, Inc · FC034955 · overseas company

Registered
UK establishment opened 25 Jan 2017, registration filed 16 Jan 2018
Incorporated in
Delaware, number 6453634, Wilmington
Officers
John William Cassidy, director; Emil Hewage, secretary
Status
Active, with accounts recorded as due to 31 Jan 2018 and none filed since

Reading the filings

  1. The parent raised it, the subsidiary spent it.The UK company never issued shares to an investor. It was funded by its Delaware parent, first as debt and then as equity: £1,372,755 owed at 31 January 2018, £2,321,683 a year later, then nothing, with 3,357,375 shares issued to Cambridge Cancer Genomics, Inc at £1 each in July 2020. That £3.36 million is the same order of magnitude as the $4.5 million of seed reported in the press, so most of what was raised in Delaware appears to have gone into Cambridge.
  2. Nothing in Regulation D.The records pull found no Form D under the company name and no EDGAR filing mentioning it. A Delaware company raising from angels and seed funds can use Section 4(a)(2) and file nothing, so the gap is not evidence that no money moved. It does mean the US cap table is invisible.
  3. The burn rate is readable.Accumulated losses went from £354,217 at 31 January 2018 to £3,507,815 at 31 July 2021: £3,153,598 over 42 months, an average of about £75,000 a month. Cash fell in every single period.
  4. The last operating year was tight.At 31 July 2021, weeks after the acquisition was announced, the company held £33,886 against £298,193 of trade creditors and was £150,290 in net liabilities. The final period to 30 June 2022 shows no fixed assets, £14 of debtors and £81 of trade creditors: a shell being tidied for closure.
  5. Headcount peaked early, and the filings disagree.The accounts to 31 January 2020 report an average of 18 employees with 12 the year before. The accounts filed for that earlier year had reported nil. Press reported 25 staff in 2019, which would be the group rather than the UK entity.
  6. Three totals, and no filing that settles them.Cambridge Judge Business School lists £7.2 million raised. One private market database says $4.62 million across three rounds. Forbes and Business Weekly both said about $4.5 million in early 2019. None of the accounts were audited, so no figure in the set was ever checked by an auditor.

Commercial signals

Signal Detail Source type
Revenue No turnover disclosed in any filing. The accounts are filleted balance sheets, permitted for small companies. Public record
Customers A pilot with the Comprehensive Blood and Cancer Center, Bakersfield, from 2017. No named paying customer found. Company-stated
Partners Genomics England Discovery Forum, Mar 2019. Dante Labs and Nonacus profiling service, Jun 2020. Partner-stated
Evidence One peer reviewed paper (Jun 2021), one ESMO abstract on OncOS (2019), five NeurIPS papers (2019). No registered trial. Public record
Public funding No Innovate UK award found. UKRI records the company only as a studentship partner and a linked organisation. Public record
Exit Acquired by Dante Labs, 23 Jun 2021. Terms not disclosed by either side. Company release

What to watch

  • The overseas registration, still active at Companies House with no accounts on file.
  • Any disclosure of the Dante Labs consideration. Nothing has been published by either party.
  • Whether OncOS appears in any Dante product filing or certification.
  • The gap between the £7.2 million on the Cambridge Judge ventures page and the roughly $4.5 million in contemporary reporting.

The Cambridge Cancer Genomics story on Healthcare DiscoveryHealthcare Discovery

Related companies

  • BIOS Health: Shared investor: Ame Cloud Ventures. A Cambridge company that set out to build a plug for the nervous system and now sells software that tunes nerve stimulation
  • Ananya Health: Shared investor: Company-Stated Partners. A battery powered cryoablation device built to freeze cervical precancer in clinics with no cryogen gas and no gynecologist
  • Clear Genetics: Shared investor: Company-Stated Partners. Three founders, one of them the CEO’s father, built a chatbot that walked patients through genetic testing
  • Osmind: Shared investor: Ame Cloud Ventures. An electronic health record for psychiatry practices delivering ketamine, esketamine and TMS, and a real world evidence business built on what those practices record

Sources

  1. Public recordRegister entry and filing history, company 10583580Companies House
  2. Public recordOfficers, PSC and charges, company 10583580Companies House
  3. Public recordAnnual accounts, company 10583580, five filings 2018 to 2022Companies House
  4. Public recordOverseas company record FC034955Companies House
  5. Public recordRecords pull: SEC EDGAR, FDA, ClinicalTrials.gov, NIH, PubMedCompiled Sep 23, 2026
  6. Public recordOrganisation and project recordsUKRI Gateway to Research
  7. IndependentCambridge Cancer Genomics offers a better way to gauge effective cancer treatmentsTechCrunch · Aug 22, 2017
  8. IndependentCancer AI business set for significant funding roundBusiness Weekly · Feb 15, 2019
  9. Independent2019 Europe 30 Under 30, Science & HealthcareForbes · Feb 12, 2019
  10. IndependentPersonalised AI oncology role for Cambridge Cancer GenomicsCambridge Independent · Dec 29, 2019
  11. IndependentNew York’s Dante Labs acquires Cambridge Cancer GenomicsCambridge Independent · Jul 1, 2021
  12. DatabaseCompany profile and funding historyTracxn
  13. CompanyCambridge Cancer Genomics ventures listingCambridge Judge Business School
  14. InvestorCCG.ai acquired by Dante LabsPi Campus · Jul 2, 2021
  15. CompanyDante Labs acquires Cambridge Cancer GenomicsGlobeNewswire · Jun 23, 2021

Compiled from Companies House, SEC, UKRI and other public records and published reports as of September 23, 2026. Figures drawn from Companies House filings reflect the balance sheet date of each filing, and all of the company’s accounts were unaudited. Healthcare Venture Capital Fund holds no position in Cambridge Cancer Genomics. This page is not an offer to sell or a recommendation to buy any security.